Monday, 3 June 2013

Analysis Revealed that Glaxo Drugs Can Prolong Lives of Ovarian Cancer Patients up to 17 Months

Analysis Revealed that Glaxo Drugs Can Prolong Lives of Ovarian Cancer Patients up to 17 Months

Analysis Revealed that Glaxo Drugs Can Prolong Lives of Ovarian Cancer ... 
Headlines & Global NewsThe researchers conducted a large-scale Phase 3 trial on women with advanced ovarian cancer. The test was successful as it prolonged the lives of the patients without getting their disease worse for an average of 5.6 months. The American Society ... 

http://www.hngn.com/articles/4251/20130601/analysis-revealed-glaxo-drugs-prolong-lives-ovarian-cancer-patients-up.htm

According to the study presented last Saturday at the annual meeting of the American Society of Clinical Oncology in Chicago, the oral drug Votrient- with generic name pazopanib formulated to block tumor growth- may be used as a maintenance drug by ovarian cancer patients after the surgery and chemotherapy

No comments:

Post a Comment